Sanofi has scrapped plans to seek approval of amlitelimab in atopic dermatitis, concluding the OX40-ligand monoclonal antibody would not represent a meaningful improvement over the standard of care for moderate-to-severe patients. The decision marks an about-face after Sanofi had evaluated amlitelimab as a potential successor to Dupixent. Sanofi said the move is part of an ongoing pipeline assessment, effectively pausing a development track that had drawn attention as a large potential franchise candidate. Separately, the company’s abandonment follows the broader reevaluation of late-stage priorities as competitive standards in immunology remain difficult to displace. For biotech investors and BD teams, the read is straightforward: even for assets positioned as Dupixent-next candidates, payers and clinicians appear to demand clearer differentiation—forcing companies back to pipeline triage.